• Reyon Pharmaceutical cut its third-series convertible bond conversion price to KRW 9,795 from KRW 10,170, effective Oct. 26, 2026, following share-price declines.
• The adjustment increases shares issuable upon conversion to 8,667,687 from 8,348,082 on KRW 84.9 billion of outstanding bonds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reyon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261026800475), on October 26, 2026, and is solely responsible for the information contained therein.